OriCell Reports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022


Shanghai, PRC, June 5th, 2022 — OriCell Therapeutics Co., Ltd (OriCell) today reported the positive results from Phase I POLARIS study, an investigator-sponsored study evaluating Ori-CAR017, an autologous GPRC5D-directed CAR-T cell, in patients with relapsed/refractory multiple myeloma at American Society of Clinical Oncology(ASCO) annual meeting.

  • • Single Infusion of OriCAR-017 Demonstrates an Early, Deep and Durable Responses at All Dose Levels in Heavily Pretreated RRMM Patients, including Patients Who Relapsed from BCMA CAR-T Therapy.  

  • • Overall Response Rate(ORR) was 100% with Complete Response (CR)/ stringent Complete Response (sCR) rate of 60%,including Five patients with prior BCMA CART therapy achieved 2 sCR, 2 VGPR and 1PR. Patient medium follow up time 175 days (range 35-281). 

  • • All patients were progression free without additional therapy at data cutoff.  Results Highlights a Major Advance for OriCAR-017 Future Potential in RRMM Setting, regardless prior BCMA Targeted Therapy.

  • • No Dose Limiting Toxicities (DLTs) or Serious Adverse Events (SAE) was observed. No Immune effector Cell Associated Neurotoxicity Syndrome(ICANS). Only Grade 1/2 Cytokine Release Syndrome(CRS). Most common Grade 3/4 AE was cytopenia, mainly due to lymphodepleting chemotherapy.


“We are delighted to share the FIH data from our Phase I POLARIS study, we strongly believe these data has demonstrated our advantages from the proprietary platforms for CAR-T optimization structure. Next step, we will be focusing on filling an IND with the NMPA and FDA for Ori-CAR017.” said Dr. Helen Yang, Chairman and CEO of OriCell. “We look forward to continue developing novel cell therapies, to provide patient with better treatment option in the future.”

Prof. He Huang, M.D., Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University said: “Multiple Myeloma (MM) remains incurable with extremely low overall survival for relapsed/refractory patients. Therapies using newer targets are urgently needed. The data presented at ASCO 2022 demonstrated that OriCAR-017 is a safe and effective treatment for patients with RRMM who received multiple lines of therapy, especially those who relapsed after BCMA-targeted therapy. I look forward to advancing the research of Ori-CAR017, a first-in-class autologous GPRC5D-directed CAR-Tcell, with OriCell, so that patients can benefit from clinical results as soon as possible.”

Details for the Oral Presentation at ASCO 2022 are as follows: 

Hematologic Malignancies—Plasma Cell Dyscrasia

Session Type: Oral Abstract Session

Date and Time: 06/05/2022, 8:00 AM - 11:00 AM

Presentation Time/Duration: 9:12 AM - 9:24 AM

Abstract Title: Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).

Abstract ID: 8004

About OriCell Therapeutics

Founded in 2015, OriCell Therapeutics aims to develop novel immuno-therapies to satisfy the globally unmet clinical needs.  OriCell have constructed 4 major patented technology platforms: Ori®Ab antibody discovery technology platform, Ori®CAR CAR-T technology platform with high memory and high vitality, Ori®TIL stable and controllable cell culture platform for efficient expansion, and Ori®UCAR general-purpose, convenient and efficient CAR-T technology platform.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.